CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically in the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services. Clients are supported from target identification through non-clinical development and product release. The operating model is organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8% of that total, RMS contributing 21.1%, and Manufacturing contributing 19.1%.

The company maintains a broad physical footprint, currently operating in more than 120 sites across over 20 countries worldwide. Scale and geographic reach are therefore meaningful features of the business model, but the margin and return figures do not currently point to a wide, profitable moat. The trailing net margin is -6.0% and return on equity is -7.7%. Those negative numbers imply that, over the relevant measurement period, the business has not converted revenue into shareholder profit. Any competitive-position assessment must acknowledge that the company is currently loss-making despite its segment leadership and global presence.

Financial posture

At a market capitalization of $14.2 billion and a recent price of $294.59, Charles River Laboratories is a mid-to-large cap healthcare name. The valuation metrics, however, are unusual because the company is not currently profitable on a trailing basis. The P/E ratio is -60.9, reflecting negative earnings. That same unprofitability appears in the net margin of -6.0% and the ROE of -7.7%. A beta of 1.41 indicates the stock has historically moved with more volatility than the overall market, which is consistent with a business tied to biotech funding cycles, client project timing, and turnaround expectations.

From a technical snapshot, the stock is trading above its 50-day exponential moving average of $268.35, and the RSI reads 60.9, neither of which carries intrinsic bull or bear meaning on its own. What matters for context is that the $14.2 billion valuation exists alongside negative trailing earnings. Investors evaluating the name are therefore not pricing a steady-profit compounder in the current data; they are weighing a strategic restructuring story against a backdrop of recurring revenue from a global services footprint.

Strategic priorities & outlook

The company’s most recent SEC 10-K filing outlines a near-term agenda centered on operational simplification and portfolio integration. Management intends to optimize the global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. It also plans to integrate Discovery Services and Safety Assessment into one overarching DSA organization, combining the sales force and leadership approach.

Strategically, Charles River is pursuing the objective of being the “scientific partner of choice” by delivering a comprehensive and integrated portfolio designed to accelerate biomedical research and therapeutic innovation. A separate operational priority is to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. In January 2026, the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. Those disclosures tie the negative current margins to a self-described restructuring narrative: site consolidation, segment integration, and supply-base investments.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research company, Charles River Laboratories carries exposure to several macro and geopolitical factors common to the industry. The business is sensitive to regulatory oversight, including FDA and equivalent international standards for safety assessment, GLP compliance, and animal research protocols. Changes in animal-welfare regulations or restrictions on the use of non-human primates in research could affect both supply availability and operating costs, particularly for the RMS and DSA segments.

The company’s global presence across more than 20 countries introduces foreign-exchange and trade-policy exposure. Tariffs, cross-border licensing requirements, and logistics costs can influence margins on research models and biologics testing services. The business is also exposed to broader biotech and pharmaceutical R&D spending trends: when clients delay or cancel early-stage programs, demand for discovery and safety-assessment services typically weakens. Workforce costs for specialized scientific labor represent another macro-linked pressure, because competition for toxicology, pathology, and biologics talent is intense in the contract research sector.

Recent developments

On September 25, 2026, MarketBeat reported that Charles River is targeting 5%-7% growth and $300 million in savings under a 2030 plan. The prior day, September 24, 2026, the company held its 2026 Investor Day. Business Wire highlighted a refreshed strategic vision aimed at driving profitable growth and long-term value creation, while Seeking Alpha published the Analyst/Investor Day transcript for those wanting management’s exact commentary. Also on September 24, 2026, Defense World ran a financial comparison between Charles River Laboratories and Adaptive Biotechnologies, framing CRL within the broader diagnostics and research peer set.

These headlines collectively point to a company in the middle of articulating a multi-year turnaround: cost targets, growth targets, and a refreshed narrative around profitable growth. The 2030 plan’s 5%-7% growth target and $300 million savings figure now sit alongside the 10-K disclosure of roughly 12 additional site closures or consolidations over the next two years.

Earnings behavior & post-earnings drift

Charles River Laboratories has delivered a perfect beat rate over the last eight reported quarters: 8 out of 8 beats, with an average earnings surprise of 9.3%. The average 5-day price move in the five trading days after earnings across those same quarters is 1.24%, classified as an “up” drift. That said, individual quarters show considerable dispersion beneath the average.

The most recent report, on August 5, 2026, delivered EPS of $3.02 against an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five days. The May 7, 2026 quarter also beat—actual EPS $2.06 versus $1.96 estimate, a 5.1% surprise—but the stock fell 2.23% the next day and 12.42% over the following five days. Earlier, the February 18, 2026 report showed EPS of $2.39 versus $2.33 estimate (2.6% surprise), with the stock up 3.95% the next day and 6.05% over five days, while the November 5, 2025 report produced EPS of $2.43 versus $2.32 estimate (4.7% surprise), rising 1.9% the next day and 2.27% over five days.

The takeaway is mechanical, not prescriptive: CRL has consistently reported EPS above the visible consensus, yet the post-earnings price reaction varies in magnitude and can be sharply negative in the five-day window even after a beat. The next scheduled release is November 4, 2026, before the market open, with the consensus EPS estimate at $2.96.